Tenax Therapeutics, Inc. (TENX): Price and Financial Metrics
GET POWR RATINGS... FREE!
TENX Stock Price Chart Interactive Chart >
TENX Price/Volume Stats
|Current price||$1.96||52-week high||$3.68|
|Prev. close||$2.03||52-week low||$0.80|
|Day high||$2.03||Avg. volume||1,436,951|
|50-day MA||$1.98||Dividend yield||N/A|
|200-day MA||$1.74||Market Cap||29.34M|
Tenax Therapeutics, Inc. (TENX) Company Bio
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. The company was founded in 1967 and is based in Morrisville, North Carolina.
TENX Latest News Stream
|Loading, please wait...|
TENX Latest Social Stream
View Full TENX Social Stream
Latest TENX News From Around the Web
Below are the latest news stories about Tenax Therapeutics Inc that investors may wish to consider to help them evaluate TENX as an investment opportunity.
In this article we will analyze whether Tenax Therapeutics Inc (NASDAQ:TENX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead […]
Tenax Therapeutics, Inc. (Nasdaq: TENX) announces inclusion in the Russell Microcap® Index after the U.S. market opens on June 28, 2021
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Tenax Therapeutics, Inc - TENX
New York, New York--(Newsfile Corp. - June 7, 2021) - Levi & Korsinsky announces it has commenced an investigation of Tenax Therapeutics, Inc (NASDAQ: TENX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/tenax-therapeutics-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation to you.Levi & Korsinsky is a nat
Tenax Therapeutics, Inc. (Nasdaq: TENX) announces first quarter 2021 financial results and provides business update.
Tenax shares rose after the company reported progress in a Phase 2 study of levosimendan to treat pulmonary hypertension and heart failure.
TENX Price Returns